Skip to main content
Premium Trial:

Request an Annual Quote

Dx Focus: Clarient to Offer BioMerieux's BRAF CDx

Premium

BioMérieux and Clarient, a GE Healthcare company, said this week that BioMérieux's molecular diagnostic test THxID-BRAF has been added to Clarient's service offerings.

The THxID-BRAF test is a real-time PCR-based companion diagnostic assay developed by BioMérieux, intended as an aid to oncologists in selecting melanoma patients who could benefit from treatments for their tumors that carry the BRAF V600E and V600K mutations. The assay received pre-market approval from the US Food and Drug Administration for commercialization in the US in May 2013.

Clarient will use THxID BRAF to aid oncologists in selecting metastatic melanoma patients whose tumors carry the BRAF V600E mutation for possible treatment with GlaxoSmithKline's Tafinlar (dabrafenib), as well as in selecting melanoma patients whose tumors carry the BRAF V600E or V600K mutation for possible treatment with Mekinist (trametinib).

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.